Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;11 Suppl 3(Suppl 3):S24.
doi: 10.1186/bcr2443. Epub 2009 Dec 18.

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Eleanor Gutteridge  1 , John F R Robertson
Affiliations

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Eleanor Gutteridge et al. Breast Cancer Res. 2009.
No abstract available

PubMed Disclaimer

References

    1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185. doi: 10.1016/S0167-6296(02)00126-1. - DOI - PubMed
    1. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 2002;20(Suppl 3):1–10. doi: 10.2165/00019053-200220003-00001. - DOI - PubMed
    1. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris M. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885–4892. - PubMed
    1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 1839;20:4292–4302. doi: 10.1200/JCO.2002.03.100. - DOI - PubMed
    1. Baselga J, Yano S, Giaccone G, Nakagawa K, Tamura T, Douillard J, Nishiwaki Y, Vansteenkiste JF, Kudou S, Rischin D, Eek RW, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Fukuoka M. Initial results from a phase II trial of ZD-1839 (IRESSA) as second and third line monotherapy for patients with advanced non-small cell lung cancer (IDEAL-1) Program and abstracts of the 2001 AACR-NCI-EORTC International Conference - Molecular Targets and Cancer Therapeutics. October 29-November 2, 2001; Miami Beach, Florida. Abstract 630A.